Valuation: AstraZeneca PLC

Market Cap 245B 212B 199B 181B 340B 23,437B 346B 2,331B 911B 11,736B 920B 900B 39,002B P/E 2026 *
20.2x
P/E 2027 * 17.6x
Enterprise Value 264B 228B 215B 195B 367B 25,285B 373B 2,515B 983B 12,662B 993B 971B 42,077B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 3.84x
Free-Float
96.63%
Yield 2026 *
2.1%
Yield 2027 * 2.23%
1 day+0.27%
1 week-1.75%
Current month-9.30%
1 month-6.10%
3 months-15.12%
6 months-19.35%
Current year-18.06%
1 week 40.86
Extreme 40.86
42.1
1 month 39.97
Extreme 39.97
45.5
Current year 39.97
Extreme 39.97
53.8
1 year 37.3
Extreme 37.3
53.8
3 years 29.05
Extreme 29.05
53.8
5 years 28.2
Extreme 28.2
53.8
10 years 28
Extreme 28
53.8
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-1.75% - - 245B
-1.56%-0.11%+73.06%+120.16% 1,078B
-0.48%+0.41%+48.99%+50.09% 632B
-0.34%+1.36%+21.84%+63.77% 443B
-1.99%-3.32%+41.98%+34.08% 356B
-1.05%-2.81%+24.22%+34.67% 289B
-2.12%-3.67%-1.09%+3.11% 245B
-1.27%+0.31%+42.00%+57.96% 226B
-1.19%-3.41%-9.18%-52.41% 204B
-0.23%+3.60%+15.95%+72.82% 171B
Average -1.01%+1.43%+28.64%+42.69% 404.85B
Weighted average by Cap. -1.10%+1.30%+41.55%+62.36%

Financials

2026 *2027 *
Net sales 63.25B 54.63B 51.33B 46.69B 87.77B 6,048B 89.22B 601B 235B 3,029B 237B 232B 10,065B 66.85B 57.74B 54.26B 49.35B 92.77B 6,393B 94.3B 636B 249B 3,201B 251B 246B 10,638B
Net income 12.07B 10.42B 9.8B 8.91B 16.75B 1,154B 17.03B 115B 44.88B 578B 45.32B 44.33B 1,921B 13.72B 11.85B 11.13B 10.12B 19.03B 1,312B 19.35B 130B 51B 657B 51.49B 50.38B 2,183B
Net Debt 19.33B 16.69B 15.69B 14.26B 26.82B 1,848B 27.26B 184B 71.86B 925B 72.56B 70.98B 3,075B 11.66B 10.07B 9.46B 8.61B 16.18B 1,115B 16.45B 111B 43.35B 558B 43.77B 42.82B 1,855B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
13/08/26 USD 40.97 +0.27% 61
12/08/26 USD 40.86 -0.87% 10
11/08/26 USD 41.22 -2.09% 64
10/08/26 USD 42.10 +1.03% 3
07/08/26 USD 41.67 -0.07% 18
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
158.02USD
Average target price
211.68USD
Spread / Average Target
+33.95%

Quarterly revenue - Rate of surprise